| A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | AA | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | Company | Founded | Size | Category | HQ in waltham? | Description | |||||||||||||||||||||
2 | A/F Protein | 1994 | Healthcare; biotech | Yes | A/F Protein is a company that produces antifreeze proteins purified from natural sources. | ||||||||||||||||||||||
3 | Abcam | 1998 | 1,100+ | No | |||||||||||||||||||||||
4 | Acorda Therapeutics | 1995 | 474 | No | |||||||||||||||||||||||
5 | Adagio Therapeutics | 2020 | 74 | healthcare; biotech; pharma; drug development | Yes | Adagio is a clinical-stage biopharmaceutical company focusing on the discovery and development of antibody-based solutions for infectious diseases with pandemic potential. It develops ADG20 for the treatment and prevention of coronavirus disease 2019 (COVID-19), the disease caused by the virus SARS-CoV-2 and its variants. Its portfolio includes non-competing antibodies with distinct binding targets, enabling a strategy that can avoid viral escape. The company also researches additional neutralizing antibodies, such as ADG10, for potential use in combination with ADG20. | |||||||||||||||||||||
6 | Alacrita | 2009 | 29 | No | |||||||||||||||||||||||
7 | albany Molecular Research | 1991 | 2,270 | No | |||||||||||||||||||||||
8 | Alere | 1981 | 2,781 | healthcare; biotech; medical diagnostics; clinics | Yes | Alere provides diagnostics and health management solutions. The Company's products and services are focused on infectious disease, cardiology, oncology, drugs of abuse and women's health. Its brands range from over-the-counter tests to lab-based diagnostics to integrated home monitoring solutions. Alere's brands include Acceava Mono cassette, Alere Home Monitoring, AtheNA Multi-Lyte Test System, BinaxNOW, Cholestech LDX, Clearview iFOB Complete, Determine HBsAg, DoubleCheckGold and ImmunoComb. | |||||||||||||||||||||
9 | Alkermes | 1987 | 2,250 | No | |||||||||||||||||||||||
10 | Alloy Therapeutics | 2017 | No | ||||||||||||||||||||||||
11 | AMAG Pharmaceuticals | 1981 | 440 | Yes | |||||||||||||||||||||||
12 | American Research Products | 1994 | 2 | healthcare; biotech; chemicals | Yes | American Research Products (ARP) is a company specializing in chemistry and biomedical research products. It provides phosphorylated, secondary, monoclonal, recombinant, tag, and control antibodies, and more. The company serves research laboratories in hospitals, universities, and biotech firms. | |||||||||||||||||||||
13 | Apellis Pharmaceuticals | 2008 | 235 | No | |||||||||||||||||||||||
14 | Ardelyx | 2007 | 88 | No | |||||||||||||||||||||||
15 | Arrakis Therapeutics | 2015 | 72 | healthcare; biotech; pharma; drug devleopment; genetics; oncology | Yes | Arrakis Therapeutics is a biopharmaceutical company which offers a drug discovery platform intended to target RNA. The Company develops an internal product pipeline of RNA-targeted small molecules focused on neurology, oncology, and rare genetic disorders. It offers scientific platforms, such as TRYST, MARS, PEARL-Seq, to identify tractable RNA targets, design drug molecules, and select candidates for clinical development. | |||||||||||||||||||||
16 | Arsanis | 2010 | 43 | No | |||||||||||||||||||||||
17 | Arsenal Medical | 2005 | 34 | Yes | |||||||||||||||||||||||
18 | AstraZeneca | 1999 | 76,100 | No | |||||||||||||||||||||||
19 | Avedro | 2008 | 122 | Yes | |||||||||||||||||||||||
20 | Axial Biotherapeutics | 2013 | healthcare; biotech; pharma | Yes | Axial is based on the work of California Institute of Technology professor Sarkis Mazmanian. In mouse models, his lab has shown a connection between neurological disorders and interventions in the gut microbiome. Axial intends to expand on these discoveries to find pathways and mechanisms amenable to biotherapeutic intervention. Initial disease targets include autism and Parkinson’s disease. Technology that Axial has licensed from Caltech includes Mazmanian’s work involving Bacteroides fragiles. Raising the level of these gut bacteria can reduce autism-like behavior in engineered mice. | ||||||||||||||||||||||
21 | Azzur Group | 2010 | 316 | No | |||||||||||||||||||||||
22 | B&v Testing | 1978 | Yes | ||||||||||||||||||||||||
23 | Benchmark Senior Living | 1997 | 1,560 | Yes | |||||||||||||||||||||||
24 | Bio-Techne | 1981 | 2,600 | No | |||||||||||||||||||||||
25 | Biogen | 1978 | 7,400 | No | |||||||||||||||||||||||
26 | Biomodels | 1997 | 31 | healthcare; biotech; contractor; pharma | Yes | Biomodels is a preclinical contract research organization. It specializes in the testing and evaluation of drugs for pharmaceutical and biotechnology companies. | |||||||||||||||||||||
27 | BioPoint | 2011 | 58 | No | |||||||||||||||||||||||
28 | BiotechPharma | 2004 | 153 | No | |||||||||||||||||||||||
29 | Biovica | 2009 | 20 | No | |||||||||||||||||||||||
30 | Blossom Innovations | 2011 | Yes | ||||||||||||||||||||||||
31 | Blue Therapeutics | 2014 | 4 | Yes | |||||||||||||||||||||||
32 | Boston Molecules | Yes | |||||||||||||||||||||||||
33 | Boston Neurosciences | 2006 | 5 | Yes | |||||||||||||||||||||||
34 | BostonGene | 2015 | 157 | healthcare; technology; biotech; therapy | Yes | BostonGene operates as a biomedical software company providing solutions for fighting cancer. It offers a cloud platform which performs analytics to aid clinicians in their evaluation of viable treatment options for each patient's individual genetics, tumor and tumor microenvironment, clinical characteristics and disease profile. The Company's mission is to enable physicians to provide every patient with the highest probability of survival through optimal cancer treatments using personalized therapies. | |||||||||||||||||||||
35 | Cato Research | 1988 | 105 | No | |||||||||||||||||||||||
36 | CATO SMS | 2019 | 297 | No | |||||||||||||||||||||||
37 | Chiasma | 2001 | 48 | No | |||||||||||||||||||||||
38 | CorEvitas, LLC | Yes | https://www.corevitas.com/ | ||||||||||||||||||||||||
39 | Corindus Vascular Robotics | 2002 | 90 | Yes | |||||||||||||||||||||||
40 | CorneaGen | 2016 | 138 | No | |||||||||||||||||||||||
41 | Corvidia | 2015 | healthcare; biotech; therapy | Yes | Corvidia is a biotechnology company. It develops next-generation precision cardiovascular therapies. The Company's cardiovascular therapies help to identify patients with unique sensitivity to specific biologic pathways. | ||||||||||||||||||||||
42 | Cotiviti | 1979 | 3,810 | No | |||||||||||||||||||||||
43 | CROMSOURCE | 1997 | 237 | No | |||||||||||||||||||||||
44 | Cugene | 13 | healthcare; bioengineering; biotech; drug development; oncology; pharma | Yes | Cugene is a company dedicated to the discovery and development of medicines for treating cancer and inflammatory disorders. It utilizes bioengineering to limit unwanted side effects on neighboring healthy tissues. | ||||||||||||||||||||||
45 | Deciphera Pharmaceuticals | 2003 | 350 | Yes | |||||||||||||||||||||||
46 | Dentsply Sirona | 2016 | 15,200 | No | |||||||||||||||||||||||
47 | Devoted Health | 2017 | 669 | Yes | |||||||||||||||||||||||
48 | Dragonfly Therapeutics | 2015 | 127 | Yes | |||||||||||||||||||||||
49 | Dynamicure Biotechnology | ||||||||||||||||||||||||||
50 | Dyne therapeutics | 2018 | 79 | Yes | |||||||||||||||||||||||
51 | Echosens | 2001 | 214 | No | |||||||||||||||||||||||
52 | Eduation Development Center | 1958 | 3,280 | Yes | |||||||||||||||||||||||
53 | ElevateBio | 2017 | 254 | No | |||||||||||||||||||||||
54 | Eloxx Pharmaceuticals | 2013 | 29 | Yes | |||||||||||||||||||||||
55 | Engene | 1999 | 57 | No | |||||||||||||||||||||||
56 | Entasis Therapeutics | 2015 | 33 | Yes | |||||||||||||||||||||||
57 | Eurofins | 1987 | 49,070 | No | |||||||||||||||||||||||
58 | Evidera | 2013 | 617 | No | |||||||||||||||||||||||
59 | Exosome Diagnostics | 2008 | 86 | Yes | |||||||||||||||||||||||
60 | EyeGate Pharmaceuticals | 1998 | 10 | Yes | |||||||||||||||||||||||
61 | Fortress Biotech | 2006 | 93 | No | |||||||||||||||||||||||
62 | Fresenius | 1912 | 310,840 | No | |||||||||||||||||||||||
63 | Fresenius Medical Care | 1996 | 28,360 | Yes | |||||||||||||||||||||||
64 | Galapagos | 1999 | 1,330 | No | |||||||||||||||||||||||
65 | Glytec | 2006 | 109 | Yes | |||||||||||||||||||||||
66 | GoodCell | 2016 | 38 | Yes | |||||||||||||||||||||||
67 | Hemera Biosciences | 2010 | 2 | Yes | |||||||||||||||||||||||
68 | Imaging Endpoints | 2009 | 136 | No | |||||||||||||||||||||||
69 | Immunitas Therapeutics | 2019 | 26 | Yes | |||||||||||||||||||||||
70 | ImmunoGen | 1981 | 79 | Yes | |||||||||||||||||||||||
71 | Interwell Health | 2019 | 11 | Yes | |||||||||||||||||||||||
72 | JCW | 1852 | Yes | ||||||||||||||||||||||||
73 | KEW | 2011 | 20 | Yes | |||||||||||||||||||||||
74 | Krystal Biotech | 2017 | 75 | No | |||||||||||||||||||||||
75 | Linus Health | start up | 52 | Yes | |||||||||||||||||||||||
76 | Liofilchem, Inc. | 1983 | No | http://liofilcheminc.com/ | |||||||||||||||||||||||
77 | LLX Solutions | 2011 | 58 | Yes | |||||||||||||||||||||||
78 | LUMICKS | 2014 | 191 | No | |||||||||||||||||||||||
79 | MD Connect | 2017 | 20 | Yes | |||||||||||||||||||||||
80 | MEDITECH | 1969 | 3,530 | No | |||||||||||||||||||||||
81 | MicroMedicine | 2016 | 3 | Yes | |||||||||||||||||||||||
82 | Miltenyi Biotec | 1989 | 1,810 | No | |||||||||||||||||||||||
83 | Minerva Biotechnologies | 1999 | 22 | Yes | |||||||||||||||||||||||
84 | Minerva Neruosciences | 2007 | 13 | Yes | |||||||||||||||||||||||
85 | Mobile Heartbeat | 2010 | 88 | Yes | |||||||||||||||||||||||
86 | Morphic therapeutic | 2015 | 76 | Yes | |||||||||||||||||||||||
87 | MSM Protein Technologies | 2005 | 4 | Yes | |||||||||||||||||||||||
88 | Mythic Therapeutics | Yes | |||||||||||||||||||||||||
89 | NanoEnTek | 2000 | 65 | No | |||||||||||||||||||||||
90 | naviHealth | 2012 | 1,930 | No | |||||||||||||||||||||||
91 | Nocion therapeutics | 2018 | 3 | Yes | |||||||||||||||||||||||
92 | Northway Biotech | 2014 | Yes | ||||||||||||||||||||||||
93 | NxStage Medical | 1998 | 713 | No | |||||||||||||||||||||||
94 | Olaris | 2013 | 13 | Yes | |||||||||||||||||||||||
95 | Onco360 | 2003 | 235 | No | |||||||||||||||||||||||
96 | Oncopeptides | 2000 | 294 | No | |||||||||||||||||||||||
97 | OncXerna | 2018 | Yes | ||||||||||||||||||||||||
98 | Orionis Biosciences | 2015 | 38 | Yes | |||||||||||||||||||||||
99 | Palleon Pharmaceuticals | 2016 | 28 | Yes | |||||||||||||||||||||||
100 | Parexel International | 1983 | 15,520 | No |